Condition

Metastatic Clear Cell Renal Cell Carcinoma clinical trials and research

• 13Clinical trials
• 19Countries

Newest Metastatic Clear Cell Renal Cell Carcinoma clinical trials

All recruiting trials (13)

• Casdatifan for refractory metastatic clear cell kidney cancer

  This pilot, first-in-human study tests whether taking casdatifan by mouth can help people with metastatic clear cell renal cell carcinoma that has not responded to prior therapies.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07748988

• Imaging study to see how the imaging agent distributes in metastatic clear cell RCC

  This imaging study tests an imaging agent in adults with metastatic clear cell renal cell carcinoma to see how it spreads and what dose is needed.

  Recruiting at 4 sites Early Phase 1 RayzeBio, Inc. · Saint Leonards, New South Wales and 5 other locations · NCT07671417

• CD70-Targeted Imaging-Guided Pause of Therapy in Metastatic Clear Cell RCC

  This study tests whether patients with metastatic clear cell RCC who respond to first-line PD-1/PD-L1 inhibitors plus VEGFR-TKI can safely pause treatment guided by CD70-targeted Immuno-PET/CT imaging.

  Recruiting at 5 sites Phase 2 Jinling Hospital, China · Nanjing, Jiangsu and 4 other locations · NCT07615348

• VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma

  This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07510334

• Adding a probiotic to standard immunotherapy for advanced kidney cancer

  This trial tests whether adding MO-03 probiotic to standard immunotherapy helps people with advanced or metastatic clear cell kidney cancer.

  Recruiting at 41 sites Phase 3 SWOG Cancer Research Network · Fayetteville, Arkansas and 40 other locations · NCT07383441

• Nivolumab and ipilimumab with or without EXL01 for advanced or metastatic clear-cell and sarcomatoid renal cell carcinoma

  This trial tests whether adding EXL01, a live Faecalibacterium prausnitzii product, to nivolumab and ipilimumab helps adults with advanced or metastatic clear-cell or sarcomatoid renal cell cancer.

  Recruiting at 2 sites Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07128680

• Casdatifan plus cabozantinib versus placebo plus cabozantinib for advanced clear cell kidney cancer

  This trial tests whether adding casdatifan to cabozantinib helps adults with advanced or metastatic clear cell kidney cancer who progressed after PD‑1 or PD‑L1 immunotherapy.

  Recruiting at 191 sites Phase 3 Arcus Biosciences, Inc. · Gilbert, Arizona and 190 other locations · NCT07011719

• Using 18F-TRX to image solid tumors

  This trial tests whether the 18F-TRX PET tracer can detect tumors in adults with advanced solid tumors such as high‑grade glioma, clear cell renal cell carcinoma, or metastatic castration‑resistant prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06942104

• Inulin gel plus ipilimumab and nivolumab for advanced kidney (renal cell) cancer

  This trial tests whether adding an inulin gel to the immunotherapy drugs ipilimumab and nivolumab helps people with locally advanced or metastatic clear cell or sarcomatoid renal cell carcinoma.

  Recruiting Phase 1/2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT06866262

• Radiopharmaceutical treatment for advanced kidney cancer using 177Lu-PSMA-617

  This study tests whether 177Lu-PSMA-617 can help adults with metastatic clear cell renal cell carcinoma that has progressed after immunotherapy and a VEGFR-TKI.

  Recruiting at 2 sites Phase 2 European Organisation for Research and Treatment of Cancer - EORTC · Caen and 1 other locations · NCT06783348

• Predicting how tumors respond to immune therapies using a live diagnostic platform

  This study is testing a new way to predict how well immune therapies will work for patients with different types of solid tumors, including early-stage and metastatic cancers.

  Recruiting at 3 sites Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT06349642

• Genetic testing to choose the best treatment for advanced kidney cancer

  This study is testing if using genetic testing to pick the best treatment can help people with advanced kidney cancer respond better to either a combination of immunotherapy drugs or a mix of immunotherapy and targeted therapy.

  Recruiting at 6 sites Phase 2 Vanderbilt-Ingram Cancer Center · Duarte, California and 5 other locations · NCT05361720

• Comparing immunotherapy with and without kidney surgery for metastatic kidney cancer

  This study is testing whether adding kidney surgery to a standard immunotherapy treatment can help people with advanced kidney cancer live longer and feel better.

  Recruiting at 340 sites Phase 3 SWOG Cancer Research Network · Birmingham, Alabama and 386 other locations · NCT04510597

Related topics

Quick answers

How many Metastatic Clear Cell Renal Cell Carcinoma clinical trials are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 19 countries. The most sites are in United States (10 trials), France (2 trials), Australia (2 trials), New Zealand (2 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1: 3, Phase 3: 3, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →